# Evaluation of Intratympanic Alpha-Lipoic Acid and Diltiazem as Alternatives to Dexamethasone in Noise-Induced Hearing Loss in a Murine Model

## TL;DR

This study tests if alpha-lipoic acid and diltiazem can help protect hearing better than dexamethasone in a mouse model of noise-induced hearing loss.

## Contribution

The study identifies alpha-lipoic acid and diltiazem as potential alternatives to dexamethasone with distinct mechanisms of action.

## Key findings

- Alpha-lipoic acid and diltiazem improved hearing thresholds and cochlear structure compared to dexamethasone alone.
- Combining dexamethasone with alpha-lipoic acid or diltiazem increased middle ear inflammation without added benefit.
- Alpha-lipoic acid and diltiazem suppressed inflammation through antioxidant mechanisms, unlike dexamethasone.

## Abstract

This study evaluates the protective effects of alpha-lipoic acid (ALA), diltiazem (DIL), and N-acetylcysteine (NAC) as potential adjunctive agents to enhance intratympanic dexamethasone (IT-DEX) therapy in noise-induced hearing loss. A two-phase experiment using C57BL/6J mice was conducted. In phase 1, candidate drugs were screened by perilymph concentration analysis using ultra-high-performance liquid chromatography, auditory brainstem response (ABR) threshold, and organ of Corti (OC) morphology. Western blot analysis evaluated inflammatory markers. Phase 2 investigated the synergistic effects of co-administration of the most promising candidates with DEX. All drugs successfully penetrated the inner ear via IT injection. In the noise-induced hearing loss model, ALA and DIL individually demonstrated significant improvements in ABR thresholds and OC morphology compared to DEX alone, while NAC showed no therapeutic benefit. Western blot analysis revealed that ALA and DIL suppressed inflammatory markers through distinct antioxidant-mediated mechanisms, contrasting with DEX’s anti-inflammatory pathway. However, combination therapy with DEX + ALA or DEX + DIL increased middle ear inflammation and failed to produce synergistic therapeutic effects. While ALA and DIL showed individual therapeutic promise through complementary mechanisms, combination with DEX did not enhance efficacy, suggesting that simple drug combinations may not translate to improved IT therapy outcomes.